CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Multibagger Pharma Stock: Strategic Merger with Diagnostics Firm to Boost Market Presence
DSIJ Intelligence
/ Categories: Trending, Multibaggers

Multibagger Pharma Stock: Strategic Merger with Diagnostics Firm to Boost Market Presence

The stock is down by 30 per cent in 1 year while gave multibagger returns of 900 per cent in 5 years.

Kopran Ltd. has announced a strategic merger with its promoter group company, Kopran Laboratories Ltd. (KLL), subject to regulatory approvals. The merger is poised to create synergies in the healthcare and diagnostics market, leveraging KLL's expertise in the fast-growing Indian diagnostics segment. KLL is known for marketing diagnostic equipment and solutions to path labs and hospitals across India, often entering long-term agreements to provide infrastructure and support services. The merger will enable Kopran to enter the USD 14 billion Indian diagnostic industry, projected to grow at a CAGR of 14 per cent over the next five years.

This strategic move will allow Kopran to capitalize on KLL's relationships and marketing capabilities, enhancing its product reach in hospitals and government institutions. Additionally, Kopran plans to leverage its manufacturing capabilities to produce diagnostic kits, aiming to increase margins and profitability. This merger is expected to be EPS accretive for Kopran, creating value for its shareholders and advancing its goal of becoming an integrated healthcare and pharma company.

Kopran Ltd. is a fully integrated pharmaceutical company engaged in the development, manufacturing, and supply of high-quality formulations and active pharmaceutical ingredients (APIs) globally. The company operates two primary business verticals: the API vertical, which contributes approximately 54 per cent of its revenue, and the formulations vertical, accounting for the remaining 46 per cent.

DSIJ’s 'Tiny Treasure' service recommends researched Small-Cap stocks with Inherent Growth Potential. If this interests you, do download the service details here.

Kopran is a leader in producing Atenolol and offers a diverse range of products, including Carbapenems, Macrolides, and Anti-Hypertensives. The company exports its products to over 50 countries, with a strong presence in African nations, the United States, and the European Union, among others. Kopran is focused on expanding its API portfolio, particularly in Carbapenem products, and aims to capture a significant share of the US Atenolol market by FY25. The company is also enhancing its manufacturing capabilities, with a new API plant expected to commence production in Q3 FY25.

Kopran Ltd. has a market capitalization of over Rs 900 crore. The stock is down by 30 per cent in 1 year while gave multibagger returns of 900 per cent in 5 years. Its Price-Earnings (PE) Ratio stands at 20.

Disclaimer: The article is for informational purposes only and not investment advice. 

Previous Article Rs 710 Crore Order Book: Defence & Semiconductor Company’s Subsidiary Mistral Unveils DCP1000 Module Based on Lattice CertusPro-NX FPGA
Next Article Rs 5,64,223 Crore Order Book: Large-cap Engineering Giant Secures Landmark Project in Hyderabad and Chennai!
Print
189 Rate this article:
4.4
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR